NEW YORK (TheStreet) -- Jim Cramer, answering viewers' Twitter(TWTR) - Get Report questions from the floor of the New York Stock Exchange, made a bullish call on Celgene(CELG) - Get Report, but sees other opportunities for investors to trim their portfolios.
Meanwhile, when it comes to the run-up in biotech stock Celgene, Cramer says there's no reason to sell it. He explains that some numbers show that shares of Celgene are still cheap, and he recommended investors continue to buy it.
In response to a viewer asking if Fitbit (FIT) - Get Report can go higher or if it's ready for a pause, Cramer noted his price target on the stock is $50. With the stock at about $48, he recommended taking a little off the table when it comes to Fitbit.
Weighing the likelihood of a deal between Microsoft (MSFT) - Get Report and Salesforce.com (CRM) - Get Report by the end of the year, Cramer said he believes Microsoft wants a lot more exposure to cloud services, while Salesforce.com founder, chairman and chief executive Marc Benioff wants a lot more time with the company.
He added that altough the two companies are very enamored of each other and there's a lot of goodwill unlike when Microsoft was run by Steve Ballmer, ultimately Cramer believes that Benioff wants Salesforce.com to remain independent.
Lastly, a viewer asked Cramer whether the disappointing box office performance of Disney's (DIS) - Get Report 'Tomorrowland' will weigh on the company's second quarter, and whether it's a better idea to buy more shares after Disney reports quarterly results on August 4.
Cramer said that investors can wait to buy more Disney, but they're probably splitting hairs.
If you have a stock question, tweet it @jimcramer using #CramerQ.
At the time of publication, Jim Cramer's charitable trust Action Alerts PLUS held no positions in stocks mentioned.